Summary. -Mx proteins belonging to the dynamin superfamily of large GTPases inhibit replication of a wide range of RNA viruses. In this study, we examined whether bovine Mx1 protein could interfere with the replication of foot-and-mouth disease virus (FMDV). For this purpose we established cloned BHK-21 cells expressing bovine Mx1 protein (BM1 cells) and infected them with FMDV serotype O. Cloned BHK-21 cells expressing neomycin resistance instead of Mx1 protein (BH1 cells) and original BHK-21 cells served as negative controls. The results showed that the expression of bovine Mx1 protein reduced viral yields by 90% and levels of viral VP1 mRNA by 60%. These findings correlated with a significant reduction of viral antigen detectable in infected cells by immunofluorescent assay. These results demonstrate that bovine Mx1 protein interferes with the replication of FMDV.
Objective Patients with non-small-cell lung cancer (NSCLC) and primary or acquired resistance do not respond to targeted drugs. We explored whether cancer cells can be cultured from liquid biopsies from patients with primary resistance to tyrosine kinase inhibitors (TKIs). We aimed to predict patients’ responses to drugs according to in vitro drug testing results. Methods Cancer cell cultures were established from the pleural effusion of a patient with TKI-resistant NSCLC using a conditional reprogramming technique. Phenotypic drug sensitivity tests were performed using the Cell Counting Kit-8 assay. We tested individual drugs and compared the synergistic and inhibitory effects of drug combinations. Results The results of our in vitro sensitivity test using the combination of cisplatin and pemetrexed were correlated with the patient’s response. Conclusion This represents the first successful report of predictive testing for combination therapy in patients with epidermal growth factor receptor-mutant NSCLC and primary TKI resistance. This strategy should be applicable to both chemotherapies and targeted therapies, and it will significantly improve the clinical treatment and management of patients with NSCLC and primary or acquired resistance to targeted therapies, as well as patients lacking targetable mutations.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.